Skip to main content

Bausch Health Companies, Inc. (BHC)

NYSE: BHC · IEX Real-Time Price · USD
28.65 0.06 (0.21%)
Oct 22, 2021 3:18 PM EDT - Market open
Market Cap10.26B
Revenue (ttm)8.48B
Net Income (ttm)-1.29B
Shares Out358.81M
EPS (ttm)-3.61
PE Ration/a
Forward PE5.26
Dividendn/a
Ex-Dividend Daten/a
Volume619,407
Open28.70
Previous Close28.59
Day's Range28.42 - 28.81
52-Week Range16.08 - 34.80
Beta1.67
AnalystsBuy
Price Target42.68 (+49.0%)
Est. Earnings DateNov 2, 2021

About BHC

Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb/International segment offers products with a focus on the vision care, surgical, and consumer and ophthalmology Rx products in the United States; and Solta products, branded an...

IndustryPharmaceuticals
Employees21,600
Stock ExchangeNYSE
Ticker SymbolBHC
Full Company Profile

Financial Performance

In 2020, BHC's revenue was $8.03 billion, a decrease of -6.67% compared to the previous year's $8.60 billion. Losses were -$560.00 million, -68.68% less than in 2019.

Financial Statements

Analyst Forecast

According to 19 analysts, the average rating for BHC stock is "Buy." The 12-month stock price forecast is 42.68, which is an increase of 48.97% from the latest price.

Price Target
$42.68
(48.97% upside)
Analyst Consensus: Buy

News

Bausch Health Announces Tom Vadaketh Will Join Bausch Pharma* As Chief Financial Officer

LAVAL, QC, Oct. 21, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that Tom Vadaketh will join the Company as Chief Financial Office...

1 day ago - PRNewsWire

Ortho Dermatologics To Present New Data At The 2021 Fall Clinical Dermatology Conference

Eight Poster Presentations Include New Analyses of ARAZLO®,   DUOBRII® and SILIQ® LAVAL, QC, Oct. 19, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Orth...

3 days ago - PRNewsWire

Bausch + Lomb: Positive Outcomes for Premium LuxSmart™ Intraocular Lenses, Following One-Year Real-World Experience

MONTPELLIER, France--(BUSINESS WIRE)--Bausch + Lomb today announced positive outcomes following the one-year real-world evaluation of its premium LuxSmart™ lens, since its European launch.

2 weeks ago - Business Wire

Bausch Health Companies Inc. Will Release Third-Quarter 2021 Financial Results On November 2

LAVAL, QC, Oct. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its third-quarter 2021 financial results on Tuesday, Nov. 2, 2021. Bausch Health will ...

2 weeks ago - PRNewsWire

Bausch's (BHC) NOV03 for Dry Eye Disease Meets Study Goal

Bausch Health (BHC) achieves study endpoints in the phase III study evaluating its investigational drug NOV03 in patients with DED associated with MGD.

3 weeks ago - Zacks Investment Research

Bausch + Lomb Announces Statistically Significant Topline Results from the Second Phase 3 Trial Of NOV03 (perfluorohe...

LAVAL, QC and HEIDELBERG, Germany, Sept. 30, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Novaliq GmbH (...

3 weeks ago - PRNewsWire

Bausch Health Releases Annual Environmental, Social and Governance Report

LAVAL, QC, Sept. 29, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today released its annual Environmental, Social and Governance (ESG) Report (pre...

3 weeks ago - PRNewsWire

Bausch Health (BHC) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 weeks ago - Zacks Investment Research

Bausch (BHC) Surges 8%: Is This an Indication of Further Gains?

Bausch (BHC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the ...

1 month ago - Zacks Investment Research

Why Bausch Health Companies Stock Zoomed 8% Higher Today

One analyst crunches the numbers to come up with a share price valuation well above current levels.

1 month ago - The Motley Fool

Is Now the Time to Ditch Pharma Stocks?

With drug pricing reform on the horizon, investors may want to analyze their allocation.

1 month ago - The Motley Fool

What Investors Can Learn From Bill Ackman's Turnaround

Bill Ackman (Trades, Portfolio) was one of Wall Street's rising stars after the financial crisis. He made a name for himself by making two significant bets the rest of the market seems to have overlooked.

Other symbols:ADPAPDHLFLOWMBINOMD
1 month ago - GuruFocus

Bausch Pays $300M For Diabetes Drug Lawsuit: Reuters

Reuters reports that Bausch Health Companies Inc (NYSE: BHC) will pay $300 million to settle an antitrust lawsuit related to illegally maintaining a monopoly on diabetes drug Glumetza. The FDA first app...

1 month ago - Benzinga

Why Is Bausch (BHC) Up 15.2% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Salix Will Share RELISTOR® (Methylnaltrexone Bromide) Data At PAINWeek 2021

Data to Feature New Health Economic Outcomes Research of Treatment of Emergency Department Patients with Opioid-Induced Constipation LAVAL, QC, Sept. 2, 2021 /PRNewswire/ -- Bausch Health Companies Inc....

1 month ago - PRNewsWire

Bausch Health Announces Participation In Upcoming Investor Conferences

LAVAL, QC, Sept. 1, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in multiple upcoming investor c...

1 month ago - PRNewsWire

Francis Chou's Chou Associates Fund Semiannual 2021 Letter

August 20, 2021

Other symbols:GSMBIOSTKRFPWFC
1 month ago - GuruFocus

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bausch Health Companies Inc. - BHC

New York, New York--(Newsfile Corp. - August 17, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Bausch Health Companies Inc. ("Bausch or the "Company") (NYSE: BHC). Such investo...

2 months ago - Newsfile Corp

3 Generic Drug Stocks to Watch Amid Pandemic & Pricing Pressure

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in the second half of 2021. Moreover, stable pricing and improving demand in some countries in 20...

Other symbols:AMPHRDYTEVA
2 months ago - Zacks Investment Research

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

2 months ago - Zacks Investment Research

Why Bausch Health Companies Is Plunging Today

The turnaround isn't happening as fast as investors expected.

2 months ago - The Motley Fool

Bausch Health (BHC) Tops Q2 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Bausch Health Misses On Q2 Sales, Cuts FY21 Outlook, Plans IPO For Medical Aesthetics Business

Bausch Health Companies Inc (NYSE: BHC) has reported Q2 revenues of $2.1 billion, +26% Y/Y, and missing the consensus of $2.12 billion. Revenue increased organically by $380 million, or 23% Y/Y.

2 months ago - Benzinga

Bausch Health Companies Inc. Announces Second-Quarter 2021 Results

LAVAL, Quebec, Aug. 3, 2021 /PRNewswire/ -- Second-Quarter 2021 Financial Results Revenues of $2.100 Billion GAAP Net Loss of $595 Million Adjusted EBITDA (non-GAAP) 1  of $826 Million GAAP Cash Generat...

2 months ago - PRNewsWire

Bausch Health Announces Plans To Pursue An Initial Public Offering Of Solta Medical

IPO Would Unlock Value in a Medical Aesthetics Leader Transaction Will Enable Bausch Health to Continue to Execute on its Previously Announced Spinoff of its Bausch + Lomb Eye Health Business LAVAL, QC,...

2 months ago - PRNewsWire